By Fineline Cube Lepu Medical (SHE: 300003) announced that MWN117 injection has received approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of overweight or obesity, advancing a novel siRNA‑based approach in one of pharmaceutical’s hottest therapeutic arenas.
Approval Summary
| Item | Detail |
|---|---|
| Company | Lepu Medical (SHE: 300003) |
| Developer | Shanghai Minwei Biotechnology Co., Ltd. (Lepu subsidiary) |
| Product | MWN117 injection |
| Drug Class | siRNA therapeutic targeting INHBE |
| Indication | Overweight or obesity |
| Regulatory Status | Clinical trial approval granted by NMPA |
| Announcement Date | 19 Aug 2026 |
Drug Profile – MWN117
- Modality: siRNA drug independently developed by Shanghai Minwei Biotechnology, a subsidiary of Lepu Medical
- Target: INHBE, a member of the TGF‑β superfamily specifically expressed in hepatocytes
- Target Biology: INHBE is associated with inhibiting lipolysis, promoting fat storage, and inducing insulin resistance
- Mechanism: MWN117 reduces lipid accumulation by downregulating INHBE gene expression
Preclinical Highlights
| Endpoint | Observation in Animal Models |
|---|---|
| Body Fat Percentage | Significantly reduced |
| Visceral Fat | Significantly reduced |
| Muscle Mass | Increased |
| Combination Potential | Expected synergistic effects with GLP‑1 receptor agonists |
The muscle‑sparing profile is notable: a key criticism of current GLP‑1‑based weight‑loss therapies is concurrent lean‑mass loss, positioning MWN117’s muscle‑mass increase as a potential differentiator.
Market Impact & Outlook
- Beyond GLP‑1 Monotherapy: The obesity drug market is rapidly evolving toward combination strategies; MWN117’s expected synergy with GLP‑1 receptor agonists could make it an attractive add‑on asset addressing body composition quality, not just weight reduction.
- siRNA in Metabolic Disease: An INHBE‑targeting siRNA leverages the growing validation of RNA interference in metabolic indications, with hepatocyte‑specific expression potentially supporting liver‑targeted delivery and differentiated safety.
- Strategic Pivot Signal: For Lepu Medical, primarily known for cardiovascular devices, an obesity siRNA program signals expansion into chronic metabolic disease therapeutics with a potentially large addressable market in China.
- Watch Items: First‑in‑human trial design and safety/tolerability readouts, early body‑composition data, and future combination studies pairing MWN117 with GLP‑1 receptor agonists.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory outcomes, and commercial expectations for MWN117. Actual results may differ due to risks including early‑stage clinical uncertainty, regulatory decisions, and competitive dynamics in obesity therapeutics.-Fineline Info & Tech